Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer PDF full book. Access full book title Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cancer by Henri Lichenstein. Download full books in PDF and EPUB format.
Author: Henri Lichenstein
Publisher:
ISBN:
Category :
Languages : en
Pages : 26
Get Book Here
Book Description
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumor cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of another chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN.RTM. (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
Author: Henri Lichenstein
Publisher:
ISBN:
Category :
Languages : en
Pages : 26
Get Book Here
Book Description
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumor cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of another chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN.RTM. (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
Author: Christiane Pienna Soares
Publisher: Frontiers Media SA
ISBN: 2889668355
Category : Science
Languages : en
Pages : 260
Get Book Here
Book Description
Author: Steven Grant
Publisher: Academic Press
ISBN: 0123943876
Category : Business & Economics
Languages : en
Pages : 290
Get Book Here
Book Description
Provides information on the exciting and fast-moving field of cancer research.
Author: Shabir Ahmad Ganai
Publisher: Springer Nature
ISBN: 9811581797
Category : Medical
Languages : en
Pages : 266
Get Book Here
Book Description
This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
Author: Julia Gajer
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 19
Get Book Here
Book Description
Author: Avineesh Singh
Publisher: LAP Lambert Academic Publishing
ISBN: 9783845417752
Category :
Languages : en
Pages : 80
Get Book Here
Book Description
Leukemia is a type of cancer caused by the acquisition of gene mutations that bestow deregulated proliferation, impaired differentiation. There is continuing interest to recognize the signaling pathways and genes that play a crucial function in carcinogenesis and the development of resistance to antitumor drugs. The histone deacetylases (HDACs) has been found to interact with many partners through complex molecular mechanism leading to the regulation of gene expression, they have obtained the interest of a large number of researchers. Several HDAC inhibitors (HDACis) have been confirmed to proficiently protect against the growth of tumor cells in vitro as well as in vivo. Thus it is expected that some of the HDACi could be potential effective anti-leukemic drugs. In this book, we have summarized the current status of different classes of HDACs, epigenesis, apoptosis and role of HDAC inhibitors in therapeutics for the treatment of different types of leukemia.
Author: Ana C. Xavier
Publisher:
ISBN: 9783030244255
Category : Oncology
Languages : en
Pages : 210
Get Book Here
Book Description
This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.
Author: Eva Sahakian
Publisher: Elsevier Inc. Chapters
ISBN: 0128059184
Category : Medical
Languages : en
Pages : 39
Get Book Here
Book Description
Histone deacetylase inhibitors (HDI) have been largely known for their ability to induce cell cycle arrest and apoptosis of tumor cells, effects that have translated into clinically significant antitumor activity against certain malignancies. In addition, there is now increasing evidence that HDIs are also endowed with immunoregulatory properties. Interestingly, while some reports have highlighted the anti-inflammatory effects of these compounds, others have shown pro-inflammatory effects triggered by HDIs in in vitro and in vivo studies. Known targets for HDIs are histone deacetylases (HDACs), enzymes that are recruited to gene promoters where they regulate transcription through histone modifications. Some HDACs, however, can also deacetylate nonhistone proteins, indicating that the role of HDACs in cell biology goes beyond their initial described effects on histones and encompasses now more complex regulatory functions. This complexity, along with the fact that most of the HDI currently in use are pan-HDI (multiple HDAC targets), might explain the divergent immunoregulatory effects of these compounds. Given this conundrum, in this chapter we have summarized the current understanding of the expression/function of specific HDACs in immune cells, knowledge that is providing important insights into their role in immunobiology and also paving the way for the development of more selective and potentially less toxic epigenetic-based approaches to effectively harness antitumor immune responses.
Author: Oliver H. Krämer
Publisher: Springer Nature
ISBN: 1071627880
Category : Science
Languages : en
Pages : 508
Get Book Here
Book Description
This fully updated edition provides a series of methods for how best to assess functions of histone deacetylases and acetyltransferases. The disease-relevance of dysregulated protein deacetylation by overexpressed or aberrantly activated histone deacetylases has spurred an intense search for novel and improved inhibitors of these enzymes, as reflected in this collection. Expert contributors explore the generation and evaluation of novel histone deacetylase inhibitors and new and improved techniques to assess acetylation-dependent molecular mechanisms in vitro and in vivo. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step and readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and up-to-date, HDAC/HAT Function Assessment and Inhibitor Development: Methods and Protocols, Second Edition serves as an ideal guide for researchers seeking to further elucidate this vital area of study.